日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Corrigendum to "A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)": [ESMO Open. Volume 10, Issue 9, (September 2025) 105571]

关于“结直肠癌患者体内剂量递增的双周三氟尿苷/替吡嘧啶联合贝伐珠单抗 II 期研究(E-BiTS 研究)”的更正:[ESMO Open. 第 10 卷,第 9 期,(2025 年 9 月)105571]

Wakabayashi, M; Taniguchi, H; Makiyama, A; Sunakawa, Y; Takeda, H; Arimizu, K; Okumura, Y; Inagaki, C; Mitani, S; Kudo, T; Yuki, S; Akazawa, N; Kudo, C; Mori, K; Matsuda, T; Muro, K

Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study

恩考拉非尼、西妥昔单抗±比美替尼治疗BRAF突变转移性结直肠癌的真实世界疗效:BEETS(JACCRO CC-18)研究

Kotani, Daisuke; Inoue, Eisuke; Denda, Tadamichi; Inagaki, Chiaki; Kashiwada, Tomomi; Mihara, Yoshiaki; Sugaya, Akinori; Suwa, Yusuke; Ohta, Takashi; Kuramochi, Hidekazu; Oshima, Kotoe; Yuki, Satoshi; Shiozawa, Manabu; Tsuji, Akihito; Muro, Kei; Ichikawa, Wataru; Fujii, Masashi; Sunakawa, Yu

A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia

一项实用性 II 期试验,评估使用免疫检查点抑制剂治疗伴有严重吞咽困难的转移性食管癌患者的治疗策略

Nagata, Y; Arai, H; Izawa, N; Inagaki, C; Sugaya, A; Hirata, K; Tsushima, T; Moriwaki, T; Masuishi, T; Nagatani, Y; Harada, K; Taguri, M; Sunakawa, Y

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial

Tucatinib 和 trastuzumab 治疗 HER2 突变转移性乳腺癌:一项 II 期篮式试验

Okines, Alicia F C; Curigliano, Giuseppe; Mizuno, Nobumasa; Oh, Do-Youn; Rorive, Andree; Soliman, Hatem; Takahashi, Shunji; Bekaii-Saab, Tanios; Burkard, Mark E; Chung, Ki Y; Debruyne, Philip R; Fox, Jenny R; Gambardella, Valentina; Gil-Martin, Marta; Hamilton, Erika P; Monk, Bradley J; Nakamura, Yoshiaki; Nguyen, Danny; O'Malley, David M; Olawaiye, Alexander B; Pothuri, Bhavana; Reck, Martin; Sudo, Kazuki; Sunakawa, Yu; Van Marcke, Cedric; Yu, Evan Y; Ramos, Jorge; Tan, Sherry; Bieda, Mark; Stinchcombe, Thomas E; Pohlmann, Paula R

Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors

晚期胃肠道肿瘤中基于循环肿瘤DNA分析的靶向治疗

Nakamura, Yoshiaki; Ozaki, Hiroshi; Ueno, Makoto; Komatsu, Yoshito; Yuki, Satoshi; Esaki, Taito; Taniguchi, Hiroya; Sunakawa, Yu; Yamaguchi, Kensei; Kato, Ken; Denda, Tadamichi; Nishina, Tomohiro; Takahashi, Naoki; Satoh, Taroh; Yasui, Hisateru; Satake, Hironaga; Oki, Eiji; Kato, Takeshi; Ohta, Takashi; Matsuhashi, Nobuhisa; Goto, Masahiro; Okano, Naohiro; Ohtsubo, Koushiro; Yamazaki, Kentaro; Yamashita, Riu; Iida, Naoko; Yuasa, Mihoko; Bando, Hideaki; Yoshino, Takayuki

A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)

一项针对结直肠癌患者,采用每两周一次的三氟尿苷/替吡嘧啶联合贝伐单抗进行剂量递增的 II 期研究(E-BiTS 研究)

Wakabayashi, M; Taniguchi, H; Makiyama, A; Sunakawa, Y; Takeda, H; Arimizu, K; Okumura, Y; Inagaki, C; Mitani, S; Kudo, T; Yuki, S; Akazawa, N; Kudo, C; Mori, K; Matsuda, T; Muro, K

Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR

全基因组DNA甲基化状态作为RAS野生型转移性结直肠癌患者一线治疗临床疗效的生物标志物:JACCRO CC-13AR

Ouchi, K; Sunakawa, Y; Tsuji, A; Shiozawa, M; Kawai, T; Yasui, H; Ota, H; Kochi, M; Manaka, D; Ohori, H; Miyake, T; Yamaguchi, T; Matsuura, M; Sagawa, T; Makiyama, A; Takeuchi, M; Ichikawa, W; Fujii, M; Ishioka, C

A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)

一项针对 BRAF V600E 突变转移性结直肠癌的艾立布林多中心 II 期研究:BRAVERY 研究 (EPOC1701)

Masuishi, T; Taniguchi, H; Kotani, D; Bando, H; Komatsu, Y; Shinozaki, E; Sunakawa, Y; Satoh, T; Nishina, T; Esaki, T; Wakabayashi, M; Nomura, S; Takahashi, K; Ono, H; Hirano, N; Fujishiro, N; Fuse, N; Sato, A; Sakamoto, Y; Kuramoto, N; Miki, I; Ichiki, H; Nakamura, Y; Sharma, G; Skrzypczak, S; Schultz, E; Kingsford, C; Ohtsu, A; Yoshino, T

Possibility of determining high quantitative fecal occult blood on stool surface using hyperspectral imaging

利用高光谱成像技术测定粪便表面高定量粪便隐血的可能性

Ikematsu, Hiroaki; Takara, Yohei; Nishihara, Keiichiro; Kano, Yuki; Owaki, Yuji; Okamoto, Ryuji; Fujiwara, Takahisa; Takamatsu, Toshihiro; Yamada, Masayuki; Tomioka, Yutaka; Takeshita, Nobuyoshi; Inaba, Atsushi; Sunakawa, Hironori; Nakajo, Keiichiro; Murano, Tatsuro; Kadota, Tomohiro; Shinmura, Kensuke; Koga, Yoshikatsu; Yano, Tomonori

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study

循环肿瘤DNA与组织和纵向循环肿瘤DNA基因分型相结合在晚期实体瘤中的益处:SCRUM-Japan MONSTAR-SCREEN-1研究

Takao Fujisawa,Yoshiaki Nakamura,Hideaki Bando,Chigusa Morizane,Masafumi Ikeda,Norio Nonomura,Nobuaki Matsubara,Hiroji Iwata,Yoichi Naito,Susumu Okano,Daisuke Aoki,Kenichi Harano,Naoya Yamazaki,Kenjiro Namikawa,Makoto Ueno,Shigenori Kadowaki,Eiji Oki,Ken Kato,Yoshito Komatsu,Taroh Satoh,Taito Esaki,Tadamichi Denda,Tetsuya Hamaguchi,Kentaro Yamazaki,Nobuhisa Matsuhashi,Hisateru Yasui,Hironaga Satake,Tomohiro Nishina,Naoki Takahashi,Masahiro Goto,Yu Sunakawa,Takeshi Kato,Tomoyuki Otsuka,Hikaru Abutani,Hanna Tukachinsky,Jessica K Lee,Geoffrey R Oxnard,Naomi Kuramoto,Satoshi Horasawa,Yasutoshi Sakamoto,Hiroya Taniguchi,Takayuki Yoshino